Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cancer remedy containing antibody against peptide encoded by exon-17 of periostin

A cancer treatment and antibody technology, which can be used in antibody medical components, medical preparations containing active ingredients, antibodies, etc., and can solve problems such as unclear functions of splice variants.

Inactive Publication Date: 2010-11-17
OSAKA UNIV
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] This suggests that the expression of the periostin gene is not only associated with the pathology of heart failure, but also with the pathology of cancer, but the function of each splice variant in the progression of cancer pathology is unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
  • Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
  • Cancer remedy containing antibody against peptide encoded by exon-17 of periostin

Examples

Experimental program
Comparison scheme
Effect test

manufacture example 1

[0052] Hereinafter, the present invention will be described in detail and concretely using examples. Example > [manufacturing example 1] Retrieval of periostin by subtraction method 1-1 Preparation of heart failure model rats and extraction of left ventricle samples Raised with high-salt food containing 8% salt from the age of 6 weeks Male Dahl has a high salt sensitivity Rats (Dahl-S) (clear water experimental material), three left ventricle were removed in the period of cardiac hypertrophy (11 weeks) and heart failure period (14 weeks).

[0053] 1-2 Preparation of mRNA Total RNA was prepared from about 500 mg of the above-mentioned left ventricle using ISOGEN (Nippon Gene) according to the method described in the manual. Next, using the Fast Track 2.0 Kit (Invitrogen), mRNA was purified from about 400 μg of total RNA mixed with 3 animals in the cardiac hypertrophy phase and heart failure phase according to the method described in the manual, and about 3 μg of mRNA were re...

manufacture example 2

[0060] [Production Example 2] Cloning of rat periostin cDNA Isolation of rat periostin cDNA, using primers designed based on the base sequence of SF014 (1) 5'-GTTCATTGAAGGTGGCGATGGTC-3' (SEQ ID NO: 15), (2) 5'-GAGATAAAATCCCTGCATGGTCCT-3' (SEQ ID NO : 16), 10 phage subpools (subpool) (about 40,000 clones) of about 4000 clones prepared by the rat aorta cDNA library (Clontech company) inserted in the λgtII vector were carried out PCR screening, Three positive subpools were obtained. For the fragments obtained by amplifying one of the subpools by the above PCR, use AlkPhos Direct TM (Amersham Pharmacia Company), using alkaline phosphatase-labeled probes for screening by hybridization, and obtained a positive clone rat periostin #1. This insert fragment was integrated into the EcoRI site of pBluescriptII (Stragene), and the full base sequence was determined according to the method of Production Example 1-5.

[0061] The obtained clone was about 3 kb in length, corresponding to ...

manufacture example 3

[0065] [Manufacturing Example 3] Construction of Myc-His-rat periostin fusion protein expression vector An expression vector having a Myc epitope and 6 histidine tags at the carboxyl terminus of the protein translated from the coding region of the rat periostin gene obtained in Production Example 2 and a CMV promoter was prepared.

[0066] First, the vector fragment obtained by digesting the pTracer-CMV2 vector (Invitrogen) with restriction enzymes EcoRI and EcoRV was ligated with the ligation kit (Takara Shuzo Co., Ltd.) obtained by digesting the pTracer-CMV2 vector with restriction enzymes EcoRI and HindIII in Production Example 2. A fragment of about 500 bp obtained by rat periostin 5'RACE#1 and a fragment of about 2780 bp obtained by digesting rat periostin #1 obtained in Production Example 2 with restriction enzymes HindIII and Hpal, and the obtained plasmid was named pTracer - CMV2 / rat periostin. The pTracer-CMV2 / rat periostin thus prepared was digested with restrictio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for cancer therapy comprising an antibody against a peptide region encoded by exon-17 of periostin. In more detail, cancer therapy containing an anti-periostin antibody that recognizes a splice variant of periostin that is specifically expressed in tissue remodeling stroma represented by cancer tissue and has an anti-cell adhesion effect A method for diagnosing cancer and a diagnostic agent using a pharmaceutical composition, or using the aforementioned anti-periostin antibody. Background technique [0002] In recent years, with the advancement of cancer treatment methods, the cure rate of cancer has steadily increased. In particular, improvements in the success rate of eradicating primary cancers by surgery, radiation therapy, or chemotherapy have contributed to its progress. However, from a global point of view, the number of deaths caused by cancer will inevitably increase gradually due...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00A61P35/04G01N33/574
CPCC07K16/22G01N33/57484A61K2039/505C07K2317/73C07K16/30C07K2316/96A61P35/00A61P35/04C07K2317/34A61K39/39541A61K39/39558C07K2317/76
Inventor 谷山义明森下龙一葛城鸣门
Owner OSAKA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com